Markets around the world, including the US and China, all took a big drop during the uncertainty surrounding President ...

Discover the latest advancements in breast cancer treatment at the 24th Annual International Congress, featuring expert ...

The ASCENT-03 trial is a phase 3 study assessing the efficacy and safety of sacituzumab govitecan compared with physician’s choice of treatment in patients with previously untreated, locally advanced, ...

Kymera Therapeutics, Inc.'s stock rose on KT-621 data, but Sanofi's exit casts doubts. A Gilead Sciences, Inc. deal offers ...

Gilead Sciences’ first quarter performance saw sales remain flat year over year, which did not meet Wall Street’s revenue ...

These four BofA Securities Growth 10 stocks come with reliable dividends and are are timely ideas for growth and income ...

The US Food and Drug Administration on Wednesday approved Gilead Sciences' twice-yearly injection to prevent HIV -- a move the company hailed as a major breakthrough in the fight against the sexually ...

In this video, Megan Kruse, MD, breast medical oncologist at Cleveland Clinic, discusses primary results from ASCENT-04 ...

Gilead's FDA-approved Yeztugo, a twice-yearly injectable HIV PrEP, showed near-perfect trial efficacy but faces backlash over its $28K annual price.

FDA approves Gilead Sciences' groundbreaking HIV prevention injection, Yeztugo, with 99.9% effectiveness, but high cost raises concerns.